Copper depletion boosts CNS leukemia therapy by inhibiting nucleotide synthesis through impairment of mitochondrial complex IV activity.
Depleting copper in leukemia cells weakens their energy production and makes them respond better to treatment in early laboratory studies.
This Nature Cancer preclinical study demonstrates that copper depletion potentiates CNS leukemia therapy by impairing mitochondrial complex IV activity, which restricts nucleotide synthesis in leukemia cells and sensitizes them to treatment. While mechanistically compelling in mouse models, translation to human CNS leukemia requires Phase 1 investigation.
What the study was
- Study design
- Preclinical mechanistic study (mouse models + cell lines)
- Population
- Mouse models of CNS leukemia; cell lines
- Category
- Drug Development
- Maturity
- Exploratory
- Journal
- Nat Cancer
Why it surfaced
Nat Cancer (high-impact), deferred from 2026-05-28 run. Preclinical only; non-human cap applied (max 5/10). Copper depletion mechanism is novel and CNS leukemia has high unmet need. Score capped at 5 per non-human scoring rule.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.